GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » ROE %

Zymeworks (Zymeworks) ROE % : -13.03% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Zymeworks ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Zymeworks's annualized net income for the quarter that ended in Dec. 2023 was $-57.93 Mil. Zymeworks's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $444.58 Mil. Therefore, Zymeworks's annualized ROE % for the quarter that ended in Dec. 2023 was -13.03%.

The historical rank and industry rank for Zymeworks's ROE % or its related term are showing as below:

ZYME' s ROE % Range Over the Past 10 Years
Min: -248.22   Med: -55.08   Max: 33.51
Current: -25.75

During the past 10 years, Zymeworks's highest ROE % was 33.51%. The lowest was -248.22%. And the median was -55.08%.

ZYME's ROE % is ranked better than
62.33% of 1362 companies
in the Biotechnology industry
Industry Median: -44.085 vs ZYME: -25.75

Zymeworks ROE % Historical Data

The historical data trend for Zymeworks's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks ROE % Chart

Zymeworks Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -68.25 -55.08 -64.29 33.51 -24.78

Zymeworks Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 367.98 -20.16 -44.36 -26.28 -13.03

Competitive Comparison of Zymeworks's ROE %

For the Biotechnology subindustry, Zymeworks's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's ROE % distribution charts can be found below:

* The bar in red indicates where Zymeworks's ROE % falls into.



Zymeworks ROE % Calculation

Zymeworks's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-118.674/( (492.956+464.806)/ 2 )
=-118.674/478.881
=-24.78 %

Zymeworks's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-57.928/( (424.344+464.806)/ 2 )
=-57.928/444.575
=-13.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Zymeworks  (NAS:ZYME) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-57.928/444.575
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-57.928 / 67.704)*(67.704 / 568.623)*(568.623 / 444.575)
=Net Margin %*Asset Turnover*Equity Multiplier
=-85.56 %*0.1191*1.279
=ROA %*Equity Multiplier
=-10.19 %*1.279
=-13.03 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-57.928/444.575
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-57.928 / -76.816) * (-76.816 / -93.5) * (-93.5 / 67.704) * (67.704 / 568.623) * (568.623 / 444.575)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7541 * 0.8216 * -138.1 % * 0.1191 * 1.279
=-13.03 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Zymeworks ROE % Related Terms

Thank you for viewing the detailed overview of Zymeworks's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zymeworks (Zymeworks) Business Description

Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Executives
Paul Andrew Moore officer: Chief Scientific Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle officer: SVP & Chief Financial Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith director, officer: Chair & CEO OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy director 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael director 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas officer: President & COO 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Troy Cox director C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton director
Kelvin Neu director 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson officer: Chief Medical Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4